oa Southern African Journal of Gynaecological Oncology - Uterine papillary serous cancer : guest editorial
There is much about the management of endometrial cancer that remains controversial. The literature contains very little good evidence to guide our practice on uterine papillary serous cancer (UPSC). UPSC is an aggressive histological subtype of endometrial cancer, accounting for less than 5% of its incidence, but 40% of its mortality. UPSC has a higher propensity for lymphovascular space invasion (LVSI), and intraperitoneal as well as extra-abdominal spread, than the more common endometrioid cancers. Approximately two thirds of women with UPSC have disease outside of the uterus at the time of diagnosis. Recurrence and mortality rates are high for all stages of this disease. Given the poor prognosis, most clinicians argue for adjuvant treatment for early-stage UPSC, but there is no standardised postoperative treatment available. The question which is difficult to answer is: "Does a combination of pelvic radiotherapy and adjuvant chemotherapy improve overall survival in this patient group?"
Article metrics loading...